Akebia reports Q2 EPS 0c vs (4c) last year

Reports Q2 revenue $62.472M, consensus $47.24M. “Vafseo U.S. product launch momentum builds as we continued to add new prescribers, increase volume with existing writers, and importantly, progress efforts to further expand patient access to the therapy,” said John P. Butler, Chief Executive Officer of Akebia (AKBA). “We are working to increase utilization at mid-sized dialysis organizations, and we expect by September, both Dialysis Clinics and Innovative Renal Care, the fourth and fifth largest dialysis organizations, will have operationalized protocols to simplify and expand Vafseo prescribing. Additionally, we are pleased that DaVita has begun ordering Vafseo to support an operational pilot in Q3, which we expect to lead to the opportunity for broad prescribing before year end. I am also excited about the progress we have made executing on our post-marketing development strategy, which is critical to our ultimate goal of making Vafseo the standard of care for the treatment of anemia in patients with chronic kidney disease.”